Study of NEO-201 in Solid Tumors Expansion Cohorts

Inclusion Criteria: * Age: \>/=18 years * Diagnosis: * Subjects must have histologically or cytologically confirmed recurrent, locally advanced unresectable or metastatic cancer confirmed by the Laboratory of Pathology, NCI * Subjects enrolled in the expansion cohorts must have advanced non-small cell lung cancer, HNSCC, uterine cancer, or cervical cancer that has progressed during or after at least one front-line standard of care treatment, including chemotherapy and/or targeted therapy * Tumor is positive for NEO-201 antigen expression (defined as at least 10% of tumor cells expressing NEO-201 target antigen). * Patient is not a candidate for potentially curative surgery or radiation. Tumor has the additional characteristics described below for the disease specific expansion cohorts: NSCLC: * Tumor(s) must express PD-L1 (TSP \> 1%) as determined by an FDA-approved test and/or is microsatellite instability-high (MSI-H) or mismatch repair deficient, and/or is tumor mutational burden-high (TMB-H) \[≥10 mutations/megabase (mut/Mb)\], as determined by an FDA-approved test. * Patients with EGFR, ALK1, ROS1 or BRAF V600E genomic tumor aberrations must have had disease progression on FDA-approved agents for these aberrations. * Patients without these genomic tumor aberrations must have received immune-checkpoint inhibitor previously, either as a single agent or in combination with chemotherapy. Cervical Cancer: • Tumor(s) express a combined positive score (CPS) \> 1,…